https://scholars.lib.ntu.edu.tw/handle/123456789/481539
標題: | Number of resected lymph nodes and survival of patients with locally advanced esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy | 作者: | JHE-CYUAN GUO CHIA-CHI LIN Ta-Chen Huang PEI-MING HUANG HUNG-YANG KUO Chang C.-H. CHIA-CHUN WANG CHIA-HSIEN CHENG KUN-HUEI YEH CHIH-HUNG HSU JANG-MING LEE |
公開日期: | 2018 | 出版社: | International Institute of Anticancer Research | 卷: | 38 | 期: | 3 | 起(迄)頁: | 1569-1577 | 來源出版物: | Anticancer Research | 摘要: | Background: The association of extended lymph node (LN) dissection with improved outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC) who received preoperative chemoradiotherapy (CRT) followed by surgery is debatable. Patients and Methods: We reviewed data from patients with esophageal cancer enrolled in three phase II clinical trials of preoperative paclitaxel and cisplatin-based CRT during 2000-2012. Patients with ESCC who underwent planned esophagectomy were enrolled. The number of resected LNs and other clinicopathological factors were analyzed regarding their impact on progression-free (PFS) and overall (OS) survival using Cox proportional hazards model. Results: In total, 139 patients were included. The median PFS and OS were 24.4 and 31.8 months, respectively. The median number of resected and positive LNs were 19 (range=2-96) and 0 (range=0-9), respectively. The mean number of positive LNs did not differ significantly among quartile groups of total resected LNs (quartile 1: 2-12, 2: 13-19, 3: 20-29, and 4: 30-96). The resected LN number analyzed as dichotomies divided by the median or as continuous variables was not associated with PFS or OS. However, in an exploratory analysis, patients of quartiles 2 and 3 had longer PFS and OS than those with quartiles of 1 and 4 in multivariate analysis (p=0.019 and 0.005, respectively). Conclusion: Although extensive LN dissection was not associated with improved survival, resection of 13-29 LNs was associated with improved survival in patients with locally advanced ESCC receiving preoperative paclitaxel and cisplatin-based CRT. ? 2018 International Institute of Anticancer Research. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85043428778&doi=10.21873%2fanticanres.12386&partnerID=40&md5=e3b6aba299d533fdaf2bca4277b0667f https://scholars.lib.ntu.edu.tw/handle/123456789/481539 |
ISSN: | 0250-7005 | DOI: | 10.21873/anticanres.12386 | SDG/關鍵字: | cetuximab; cisplatin; fluorouracil; folinic acid; paclitaxel; adult; advanced cancer; aged; cancer patient; cancer staging; cancer survival; chemoradiotherapy; Conference Paper; drug megadose; esophageal squamous cell carcinoma; esophagus resection; female; human; loading drug dose; lymph node dissection; lymph vessel metastasis; major clinical study; male; multimodality cancer therapy; overall survival; perineural invasion; preoperative care; priority journal; progression free survival; Taiwan; chemoradiotherapy; esophagus tumor; Kaplan Meier method; lymph node; middle aged; multivariate analysis; outcome assessment; pathology; phase 2 clinical trial (topic); preoperative period; procedures; proportional hazards model; squamous cell carcinoma; statistics and numerical data; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Esophageal Neoplasms; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Multivariate Analysis; Outcome Assessment (Health Care); Preoperative Period; Proportional Hazards Models |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。